130A Stock Overview
Engages in the business of small molecule drug discovery and nucleic acid drug discovery targeting mRNA. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Veritas In Silico Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥695.00 |
| 52 Week High | JP¥3,475.00 |
| 52 Week Low | JP¥637.00 |
| Beta | 0 |
| 1 Month Change | -21.91% |
| 3 Month Change | -27.38% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -72.21% |
Recent News & Updates
Recent updates
Shareholder Returns
| 130A | JP Life Sciences | JP Market | |
|---|---|---|---|
| 7D | -12.0% | -2.9% | -1.5% |
| 1Y | n/a | -13.7% | 13.7% |
Return vs Industry: Insufficient data to determine how 130A performed against the JP Life Sciences industry.
Return vs Market: Insufficient data to determine how 130A performed against the JP Market.
Price Volatility
| 130A volatility | |
|---|---|
| 130A Average Weekly Movement | 7.9% |
| Life Sciences Industry Average Movement | 5.5% |
| Market Average Movement | 3.6% |
| 10% most volatile stocks in JP Market | 7.3% |
| 10% least volatile stocks in JP Market | 1.9% |
Stable Share Price: 130A's share price has been volatile over the past 3 months compared to the JP market.
Volatility Over Time: 130A's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | n/a | Shingo Nakamura | www.veritasinsilico.com |
Veritas In Silico Inc. engages in the business of small molecule drug discovery and nucleic acid drug discovery targeting mRNA. It has strategic partnership with Liverpool ChiroChem for the mRNA-targeted drug discovery and development. The company was incorporated in 2016 and is based in Shinagawa, Japan.
Veritas In Silico Inc. Fundamentals Summary
| 130A fundamental statistics | |
|---|---|
| Market cap | JP¥4.43b |
| Earnings (TTM) | JP¥0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs 130A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 130A income statement (TTM) | |
|---|---|
| Revenue | JP¥0 |
| Cost of Revenue | JP¥0 |
| Gross Profit | JP¥0 |
| Other Expenses | JP¥0 |
| Earnings | JP¥0 |
Last Reported Earnings
n/a
Next Earnings Date
Feb 13, 2025
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did 130A perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 06:10 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | N/A |
| Annual Earnings | N/A |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Veritas In Silico Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|